X VIR (Entecavir) Tablet

Generic brands for Entecavir Tablet Available in India Brand Name Entecashiv Generic Name Entecavir Strength 0.5mg, 1mg Manufacturer Shivnaam Tradelink Llp

Description

Description

This page contains brief details about the drug entecavir, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Entecavir is an antiviral medication developed by the U.S. Food And Drug Administration for treating chronic Hepatitis B with evidence of decompensated liver disease. It was initially approved on March 29, 2005, for treating chronic Hepatitis B.

Mechanism of Action of Entecavir

Entecavir works by inhibiting the DNA synthesis in the Hepatitis B virus by competing with a natural substrate (deoxyguanosine triphosphate), reducing the viral count, and improving liver conditions.

Uses of Entecavir

Entecavir helps to treat chronic Hepatitis B virus infection.

Entecavir Dosage available

Entecavir is available in the form of a tablet and an oral solution. Take the pill on an empty stomach, at least 2 hours after and 2 hours before the next meal. The recommended Entecavir dose for adults is 0.5mg or 1mg once daily. Entecavir is not advised for use in children under two or who weigh less than 10 kg. Depending on your age, weight, and disease condition, your doctor will determine your appropriate dose and duration. Patients weighing 10kg and 32.5kg are advised to take an oral Entecavir solution. Straight from the measuring spoon, swallow it. Do not stop using this medicine unless your doctor instructs you.

 

We can ship to :

News/Updates

References

  1. Goodman & Gilman’s, The Pharmacological Basics of Therapeutics, Antiviral agents (nonretroviral), 12th edition, 2011, 1616-1617.
  2. Accord, Electronic medicines compendium (emc), [ Revised on Feb 2019] [ Accessed on 14th April 2021], https://www.medicines.org.uk/emc/files/pil.6292.pdf
  3. Bristol-Myers Squibb Company, US Food and Drug Administration, [ Revised on Dec 2010] [Accessed on 19th August 2022], https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021797s011lbl.pdf